GE Introduces Discovery LS

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

WAUKESHA, Wisconsin-GE Medical Systems, a unit of General Electric Company, has introduced the GE Discovery LS. The digital system combines anatomical imaging from the company’s fast CT scanner, the GE LightSpeed Plus, with functional imaging of metabolic activity from its most advanced positron emission tomography (PET) system, the GE Advance NXi.

WAUKESHA, Wisconsin—GE Medical Systems, a unit of General Electric Company, has introduced the GE Discovery LS. The digital system combines anatomical imaging from the company’s fast CT scanner, the GE LightSpeed Plus, with functional imaging of metabolic activity from its most advanced positron emission tomography (PET) system, the GE Advance NXi.

The Discovery LS generates high-quality PET and CT images of a patient in a single 30-minute examination. Two image data sets are registered and fused to form a single image.

The Discovery LS is currently installed for clinical use at University Hospital, Zurich, Switzerland; Johns Hopkins Medical Institutions; and Rambam Medical Center, Haifa, Israel. GE forecasts that 30 systems will be installed worldwide by the end of this year and more than 500 in the next 3 years.

Recent Videos
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Related Content